Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 256-425-9 | CAS number: 49673-81-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vitro
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- From February 6 to 21, 2014
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 014
- Report date:
- 2014
Materials and methods
- Principles of method if other than guideline:
- In the test, a cell model of dendritic cells was used to evaluate to immunological reactivity of typical immunity cells, specialised as antigen presenting cells, exposed for prolonged time (48h) to the tested product at different concentrations.
- GLP compliance:
- no
- Remarks:
- the available study was originally run not for REACH purposes; however, it is scientifically valid and well documented.
- Type of study:
- activation of dendritic cells
Test material
- Reference substance name:
- L-lysine, S-carboxymethyl-L-cysteine salt
- IUPAC Name:
- L-lysine, S-carboxymethyl-L-cysteine salt
Constituent 1
In vitro test system
- Details on the study design:
- PRINCIPLE OF THE TEST
In the skin, the dendritic cells specialized for the first contact as antigen presenting cells, are named Langerhans Cells.
Cells used are monocytes-derived immature dendritic cells from human healthy blood volunteers, as prototypic blood-derived immunologically active cells. These cells play a central role in the skin immune response towards topical products. Human primary dendritic cells are an in vitro model of Langerhans cells. The expression of two co-stimulatory molecules, CD80 and CD86 is checked, using bacterial lipopolysaccharides (LPS, generic stimulators of immune response) and nickel sulphate as two positive controls, nickel being a well known contact sensitising agent, both in in vitro and in vivo models.
When the lymphocytes T’ TCR recognize the antigen (signal 1) on the Antigen-Presenting Cell (APC), additional molecules (called co-stimulatory) on the APC’s membrane are necessary to obtain a complete functional immune response (signal 2).
The signal 2 is very important to define the kind of immune response that is going to be activated (umoral, cellular, etc.)
The costimulatory molecules CD80 and CD86 (also calle B7.1 and B7.2) are necessary to obtain an efficient antigen presentation by the T cell receptor (TCR) and hence to obtain a correct immune response.
Both these molecules are membrane glycoprotein expressed on the surface of different antigen-presenting cells (dendritic cells, Langerhans cells, monocytes/macrophages, keratinocytes) and they recognise a further molecule, a glycoprotein called CD28 on the T lymphocyte membrane.
The switching on of the ligand/receptor system CD28/B7 avoids the T cell apoptosis and sustains their proliferation and differentiation and the production of many cytokines.
In the first phase of the physiological immune response, B7.2 is expressed as default and it modulates both the Th1 and Th2 responses. As the immune response goes on, also B7.1 is up-regulated and the costimulatory signal increase, with an expansion of T cells and the production of different cytokines. B7.1 is also preferentially up-regulated during the acute phase of auto- immune response.
The increasing level of expression of CD80 and CD86 on the dendritic cells is a signal of activation of the immune response derived from the exposition to a potentially sensitising contact antigen. Functionally, the expression of co-stimulatory molecules on the dendritic cells means activation of the immunological response in terms of capability to present the antigen in the typical tissues (skin in our case), where, in vivo, the immune protective response is triggered.
SAMPLE PREPARATION
The sample was dissolved in ethanol and then diluted in the cell culture medium at different concentrations.
The product underwent a preliminary cytotoxicity screening on the cells to decide the best concentration to test it without cytotoxic effects on the cells, in order to avoid false results. Cell medium exposed to the same experimental conditions were used as a negative control.
CELL MODEL
The test is carried out on a primary cell line of dendritic cells derived from human monocytes of healthy volunteers peripheral blood . Cells are kept in RPMI 1640, FCS (10 %), GM-CSF (50 ng/ml) e IL-4 (1000 IU/ml) added.
MTT PRELIMINARY ASSAY EXECUTION
The MTT assay is simple, accurate and yields reproducible results. The key component is (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) or MTT. This product is of yellowish colour in solution. Mitochondrial dehydrogenases of viable cells
cleave the tetrazolium ring, leading to the formation of purple crystals which are insoluble in aqueous solutions. The crystals are re-dissolved in acidified isopropanol and the resulting purple solution is measured spectrophotometrically. An increase or decrease in cell number results in a concomitant change in the amount of formazan formed, indicating the degree of cytotoxicity caused by the test material.
After exposure of the cells to the test material, the cells are washed with PBS and exposed to the MTT-medium at 37 °C. At the end of the incubation period, the MTT-medium is removed and the cells receive the MTT solubilization solution. The plate is shaken on a rotatory plate shaker for 20-30 minutes, ensuring that all the crystals have dissolved from the cells and have formed a homogeneous solution.
The absorbance is measured as described with background elimination.
The results are expressed in terms of viability:
% viability = 100 × OD treated cultures / OD untreated control cultures
TREATMENT AND EXPOSURE
Following the preliminary cytototoxicity investigation, the optimal testing concentrations were defined. The sample was diluted in the cell medium at the wished final concentrations and put in contact with the dendritic cells in vitro. The exposure has been carried out for 48 h at 37 °C with 5 % CO2.
SENSITISATION ASSAY EXECUTION
After the incubation with the tested substance and the controls, cells are collected, checked under the microscope for their vitality by staining with Trypan Blue dye and counting in a cell counter chamber, washed in PBS and then marked with a fluoresceinated anti-B7.1 or B7.2 antibody.
After washing, to eliminate the excess antibody, the MFI (Mean Fluorescence Intensity) linked to the cells was evaluated by means of a flux cytofluorimeter.
This value is proportional to the expression of costimulatory molecules.
The MFI of the non-treated cells and of cells after reaction with a monoclonal isotype-matched antibody was used as an internal control (basal fluorescence).
POSITIVE CONTROLS
- nickel sulfate crystals dissolved in PBS (well-known skin sensitiser both in vitro and in vivo)
- bacterial lipopolysaccharides (LPS, generic stimulators of immune response)
Results and discussion
- Positive control results:
- sample CD80 (MFI*) CD86 (MFI*)
nickel sulfate 20 µg/ml 28.06 38.56
nickel sulfate 10 µg/ml 20.04 25.82
nickel sulfate 4 µg/ml 14.23 5.36
LPS 1 µg/ml 30.81 74.08
*MFI = mean fluorescence intensity - it is the geometric average of the fluorescence intensity of the cells decorated with fluoresceinated antibody and it is proportional to the number of stained molecules per cell.
Nickel, a prototypic sensitising substance, showed:
- high increase of both the markers, with a predominance of CD80;
- direct correlation between concentration and intensity of the response;
- relevant effects even at very low doses. Also LPS increases the expression of both the investigated markers.
The tested dose of 4 mg/ml of nickel sulphate (NiSO4×6H2O) corresponds to more or less 1 ppm of nickel, dosage that is around the minimal sensitising threshold in already sensitised individuals with irritated skin. At this dose, Ni is already able to cause an increase from 2 times upwards of the investigated molecules. The concentration that is able to cause an allergic reaction in most of the sensitive subjects is anyway around higher value, over the 100 ppm of nickel sulphate in contact with safe and intact skin.
In vitro / in chemico
Resultsopen allclose all
- Run / experiment:
- other: 10 mg/ml test substance
- Parameter:
- other: CD80 (MFI)
- Remarks:
- MFI = mean fluorescence intensity
- Value:
- -0.51
- Vehicle controls validity:
- not applicable
- Negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Remarks on result:
- no indication of skin sensitisation
- Run / experiment:
- other: 2 mg/ml test substance
- Parameter:
- other: CD80 (MFI)
- Remarks:
- MFI = mean fluorescence intensity
- Value:
- -0.45
- Vehicle controls validity:
- not applicable
- Negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Remarks on result:
- no indication of skin sensitisation
- Run / experiment:
- other: 10 mg/ml test substance
- Parameter:
- other: CD86 (MFI)
- Remarks:
- MFI = mean fluorescence intensity
- Value:
- -1.45
- Vehicle controls validity:
- not applicable
- Negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Remarks on result:
- no indication of skin sensitisation
- Run / experiment:
- other: 2 mg/ml test substance
- Parameter:
- other: CD86 (MFI)
- Remarks:
- MFI = mean fluorescence intensity
- Value:
- -1.62
- Vehicle controls validity:
- not applicable
- Negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Remarks on result:
- no indication of skin sensitisation
- Other effects / acceptance of results:
- The sample did not cause any increase in the expression of both the investigated markers.
The sample did not cause any cytotoxic effect on the cells used for the test (IC50= 50 mg/ml).
No signal related to apoptosis on the treated cells was seen.
Applicant's summary and conclusion
- Interpretation of results:
- other: not sensitising (data used as part of a weight of evidence evaluation)
- Conclusions:
- No sensitising potential was seen in the in vitro test on human dendritic cells.
- Executive summary:
Method
An in vitro test was conducted on human dendritic cells to analyse the sensitising potential of the substance. Dendritic cells were derived from human healthy blood volunteers.
Potential effects of the test substance were related to the expression of markers CD80 and CD86.
A preliminary MTT assay was run to evaluate the cytotoxicity of the substance and decide the test concentrations for the sensitisation assay. The sensitisation assay was tun at 37 °C with 5 % CO2 for 48 h using test concentrations of 10 and 2 mg/ml.
Bacterial lypopolysaccharides (LPS) and nickel sulphate were used as positive controls.
Results
The sample was not cytotoxic to the cells used for the test (IC50 = 50 mg/ml).
Positive controls were valid. The sample did not cause any increase in the expression of both markers; no apoptosis of treated cells was seen.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.